Medtronic Sales Jump 8.4%, Diabetes Spinoff Looms

Ticker: MDT · Form: 10-Q · Filed: 2025-08-26T00:00:00.000Z

Sentiment: mixed

Topics: Medical Devices, Earnings Report, Spin-off, Cash Flow, Debt Management, Cardiovascular Health, Regulatory Risk

Related Tickers: MDT, JNJ, ABT, BSX

TL;DR

**Medtronic's revenue growth is solid, but watch the cash burn and the upcoming Diabetes spin-off for future value.**

AI Summary

Medtronic plc reported net sales of $8,578 million for the three months ended July 25, 2025, an increase of 8.4% from $7,915 million in the prior-year period. Net income attributable to Medtronic slightly decreased to $1,040 million, or $0.81 per diluted share, compared to $1,042 million, or $0.80 per diluted share, in the same period last year. Operating profit rose to $1,445 million from $1,278 million, driven by higher sales and a significant reduction in certain litigation charges, net, from $81 million to $27 million. The Cardiovascular segment saw robust growth, with net sales increasing by $278 million to $3,285 million. The company announced its intent in May 2025 to separate its Diabetes business into a new independent, publicly traded company, with completion expected within 18 months. Cash and cash equivalents decreased significantly from $2,218 million at April 25, 2025, to $1,273 million at July 25, 2025, primarily due to net cash used in financing activities of $1,381 million, including $1,162 million in payments on long-term debt and $910 million in dividends. The company also decreased its accrual for Italian payback by $39 million due to a legislative decree.

Why It Matters

Medtronic's solid revenue growth, particularly in Cardiovascular, signals strong demand for its core medical devices, which is positive for investors. The planned separation of the Diabetes business could unlock value by allowing both entities to focus on their distinct strategic priorities, potentially attracting specialized investors. For employees, this separation could mean new opportunities or shifts in roles, while customers might see more focused innovation from the independent Diabetes company. In the competitive medical technology landscape, this strategic move positions Medtronic to streamline its portfolio and potentially enhance profitability, challenging rivals like Johnson & Johnson and Abbott Laboratories to adapt their own strategies.

Risk Assessment

Risk Level: medium — The company's cash and cash equivalents significantly decreased by $945 million, from $2,218 million to $1,273 million, in just three months, largely due to $1,162 million in payments on long-term debt and $910 million in dividends. This substantial cash outflow, coupled with an accumulated other comprehensive loss of $4,604 million, indicates potential liquidity management challenges or significant capital allocation decisions that bear watching.

Analyst Insight

Investors should monitor the progress and terms of the Diabetes business separation, as it could be a catalyst for value creation. Evaluate Medtronic's cash flow trends in subsequent quarters, particularly the impact of debt payments and dividend policies, to assess long-term financial health and sustainability.

Financial Highlights

debt To Equity
0.62
revenue
$8,578 million
operating Margin
16.8%
total Assets
$90,972 million
total Debt
$28,609 million
net Income
$1,040 million
eps
$0.81
gross Margin
64.9%
cash Position
$1,273 million
revenue Growth
+8.4%

Revenue Breakdown

SegmentRevenueGrowth
Cardiovascular$3,285 million+9.2%
Neuroscience$2,416 million+4.3%
Medical Surgical$2,083 million+4.4%
Diabetes$721 million+11.4%

Key Numbers

Key Players & Entities

FAQ

What were Medtronic's net sales for the quarter ended July 25, 2025?

Medtronic plc reported net sales of $8,578 million for the three months ended July 25, 2025, an increase from $7,915 million in the prior-year period.

How did Medtronic's net income attributable to Medtronic change year-over-year?

Net income attributable to Medtronic slightly decreased to $1,040 million for the three months ended July 25, 2025, compared to $1,042 million for the three months ended July 26, 2024.

What is Medtronic's strategic plan for its Diabetes business?

In May 2025, Medtronic announced its intent to separate the Diabetes business, with the goal of creating a new independent, publicly traded company. The separation is expected to be completed within 18 months of the initial announcement.

What was the change in Medtronic's cash and cash equivalents?

Cash and cash equivalents decreased by $945 million, from $2,218 million at April 25, 2025, to $1,273 million at July 25, 2025.

What contributed to the significant cash outflow in financing activities for Medtronic?

Net cash used in financing activities was $1,381 million, primarily driven by payments on long-term debt of $1,162 million and dividends to shareholders of $910 million.

How did Medtronic's Cardiovascular segment perform?

The Cardiovascular segment reported net sales of $3,285 million for the three months ended July 25, 2025, an increase from $3,007 million in the prior-year period.

What impact did the Italian payback accruals have on Medtronic's net sales?

Medtronic decreased its accrual for the Italian payback by $39 million during the three months ended July 25, 2025, which was recognized as an adjustment to net sales.

What are the terms of Medtronic's funded research and development arrangements with Blackstone?

Medtronic is eligible to receive additional funding of $355 million under these arrangements. Following regulatory approval and commercial launch, Blackstone will earn fixed regulatory and commercial milestone payments up to $1.2 billion and royalties based on sales.

What was Medtronic's operating profit for the quarter?

Medtronic's operating profit for the three months ended July 25, 2025, was $1,445 million, an increase from $1,278 million in the same period last year.

What is the current status of Medtronic's ordinary shares outstanding?

As of August 20, 2025, there were 1,282,685,882 ordinary shares, par value $0.0001, of Medtronic plc outstanding.

Risk Factors

Industry Context

Medtronic operates in the highly competitive medical device industry, facing pressure from large diversified players and specialized innovators. Key trends include the increasing adoption of minimally invasive procedures, the growing demand for connected health solutions, and a focus on value-based healthcare. Regulatory scrutiny and reimbursement policies remain critical factors influencing market access and profitability.

Regulatory Implications

Medtronic's global operations are subject to diverse regulatory environments. Changes in pricing, reimbursement, or compliance requirements, such as the Italian payback adjustments, can materially impact financial results. The company must continuously adapt to evolving regulations in key markets to maintain its competitive position.

What Investors Should Do

  1. Monitor the progress and execution of the Diabetes business separation, as it could unlock significant shareholder value or introduce unforeseen challenges.
  2. Analyze the drivers of the significant decrease in cash and cash equivalents and assess the sustainability of the company's financing activities, particularly debt repayment and dividend payouts.
  3. Evaluate the impact of international regulatory changes, such as the Italian payback adjustment, on future revenue recognition and profitability across different segments.
  4. Assess the inventory build-up ($410 million increase) and its potential implications for working capital management and future sales performance.
  5. Continue to track the performance of the Cardiovascular segment, which remains a key growth driver for the company.

Key Dates

Glossary

Certain litigation charges, net
Costs incurred related to ongoing legal disputes, net of any recoveries or settlements. (A reduction in these charges from $81 million to $27 million positively impacted operating profit this quarter.)
Italian payback accruals
Accruals set aside for potential payments related to Italian healthcare regulations or pricing adjustments. (A $39 million decrease in this accrual due to a legislative decree improved reported revenue.)
Noncontrolling interests
The portion of equity in a subsidiary that is not attributable to the parent company. (Net income attributable to Medtronic excludes the portion belonging to noncontrolling interests.)
Deferred revenue
Revenue recognized when goods or services are delivered, but payment has been received in advance. (Represents future revenue to be recognized from services or products already paid for.)
Remaining performance obligations
The total amount of consideration for future revenue from contracts that have not yet been fulfilled. (Indicates future revenue streams from existing contracts, with approximately $0.4 billion expected to be recognized over the next three years.)

Year-Over-Year Comparison

Medtronic plc demonstrated robust top-line growth in the three months ended July 25, 2025, with net sales increasing by 8.4% to $8,578 million compared to $7,915 million in the prior year. While net income attributable to Medtronic saw a slight decrease to $1,040 million from $1,042 million, operating profit improved significantly due to higher sales and reduced litigation charges. A notable shift is the substantial decrease in cash and cash equivalents, down from $2,218 million to $1,273 million, driven by significant financing outflows for debt repayment and dividends.

Filing Stats: 4,781 words · 19 min read · ~16 pages · Grade level 14.7 · Accepted 2025-08-26 17:26:56

Key Financial Figures

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Medtronic plc Consolidated Statements of Income (Unaudited) Three months ended (in millions, except per share data) July 25, 2025 July 26, 2024 Net sales $ 8,578 $ 7,915 Costs and expenses: Cost of products sold, excluding amortization of intangible assets 3,001 2,761 Research and development expense 726 676 Selling, general, and administrative expense 2,806 2,655 Amortization of intangible assets 459 414 Restructuring charges, net 45 47 Certain litigation charges, net 27 81 Other operating expense, net 70 1 Operating profit 1,445 1,278 Other non-operating income, net ( 33 ) ( 157 ) Interest expense, net 176 167 Income before income taxes 1,302 1,268 Income tax provision 255 220 Net income 1,047 1,049 Net income attributable to noncontrolling interests ( 7 ) ( 6 ) Net income attributable to Medtronic $ 1,040 $ 1,042 Basic earnings per share $ 0.81 $ 0.81 Diluted earnings per share $ 0.81 $ 0.80 Basic weighted average shares outstanding 1,281.6 1,293.3 Diluted weighted average shares outstanding 1,287.1 1,296.5 The accompanying notes are an integral part of these consolidated financial statements . 1 Medtronic plc Consolidated Statements of Comprehensive Income (Unaudited) Three months ended (in millions) July 25, 2025 July 26, 2024 Net income $ 1,047 $ 1,049 Other comprehensive income (loss), net of tax: Unrealized gain on investment securities 19 76 Translation adjustment 349 102 Net investment hedges ( 559 ) ( 206 ) Net change in retirement obligations 1 1 Unrealized loss on cash flow hedges ( 128 ) ( 66 ) Other comprehensive loss ( 318 ) ( 92 ) Comprehensive income including noncontrolling interests 729 957 Comprehensive income attributable to noncontrolling interests ( 8 ) ( 6 ) Comprehensive income attributable to Medtronic $ 720 $ 950 The accompanying notes are an integral part of these consolidated financial statements. 2 Medtronic plc Consolidated Balance Sheets (Unaudited) (

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 1. Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. The accompanying unaudited consolidated financial statements and related notes should be

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 3. Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, hypertension, neurological surgery technologies, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care products, respiratory and monitoring solutions, and diabetes conditions. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Refer to Note 17 to the consolidated financial statements for additional information regarding the Company's reporting structure. The table below illustrates net sales by segment and division and by market geography for the three months ended July 25, 2025 and July 26, 2024. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries. Worldwide Three months ended (in millions) July 25, 2025 July 26, 2024 Cardiac Rhythm & Heart Failure $ 1,712 $ 1,535 Structural Heart & Aortic 930 856 Coronary & Peripheral Vascular 643 616 Cardiovascular 3,285 3,007 Cranial & Spinal Technologies 1,211 1,147 Specialty Therapies 702 713 Neuromodulation 504 457 Neuroscience 2,416 2,317 Surgical & Endoscopy 1,612 1,544 Acute Care & Monitoring 471 452 Medical Surgical 2,083 1,996 Diabetes 721 647 Reportable segment net sales 8,506 7,967 Other operating segment (1) 33 38 Other adjustments (2) 39 ( 90 ) Total net sales $ 8,578 $ 7,915 U.S. International Three months ended (in millions) July 25, 2025 July 26, 2024 July 25, 2025 July 26, 2024 Cardiovascular $ 1,479 $ 1,403 $ 1,806 $ 1,604 Neuroscience 1,624 1,565 792 752 Medical Surgic

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) classified as other accrued expenses, and $ 683 million of distributor chargebacks were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 25, 2025, $ 983 million of rebates were classified as other accrued expenses, and $ 680 million of distributor chargebacks were classified as a reduction of accounts receivable in the consolidated balance sheet. During the three months ended July 26, 2024, the Company recognized $ 90 million of incremental Italian payback accruals resulting from the July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. During the three months ended July 25, 2025, the Company decreased its accrual for the Italian payback by $ 39 million resulting from the June 30, 2025 legislative decree published by the Italian government and formalized into law in August 2025 confirming a reduction of the amounts due for years 2015 to 2018. The changes in estimates related to the Italian payback accruals were recognized as adjustments to net sales in the consolidated statements of income. Refer to Note 16 for additional information. Other adjustments to variable consideration during the three months ended July 25, 2025 and July 26, 2024 were not material. Deferred Revenue and Remaining Performance Obligations Deferred revenue at July 25, 2025 and April 25, 2025 was $ 442 million and $ 446 million, respectively. At July 25, 2025 and April 25, 2025, $ 352 million and $ 354 million was included in other accrued expenses, respectively, and $ 91 million and $ 92 million was included in other liabilities, respectively. During the three months ended July 25, 2025, the Company recognized $ 135 million of revenue that was included in deferred revenue as of April 25, 2025. During the three months ended July 26, 2024, the Company recognized $ 108 million of revenue that was included in deferred revenue as of April 26, 2024.

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) The following table presents the classification of restructuring, associated, and other costs in the consolidated statements of income: Three months ended (in millions) July 25, 2025 July 26, 2024 Cost of products sold $ 16 $ 9 Selling, general, and administrative expenses 5 5 Restructuring charges, net 45 47 Total restructuring, associated, and other costs $ 67 $ 62 The following table summarizes the activity for the three months ended July 25, 2025: (in millions) Employee Termination Benefits Associated and Other Costs Total April 25, 2025 $ 132 $ 18 $ 150 Charges 52 21 73 Cash payments ( 70 ) ( 25 ) ( 95 ) Settled non-cash — ( 2 ) ( 2 ) Accrual adjustments (1) ( 7 ) — ( 7 ) July 25, 2025 $ 107 $ 12 $ 119 (1) Accrual adjustments primarily relate to certain employees identified for termination finding other positions within the Company. 9 Medtronic plc

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 6 . Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at July 25, 2025 and April 25, 2025: July 25, 2025 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 476 $ — $ ( 6 ) $ 469 $ 469 $ — Level 2: Corporate debt securities 3,628 23 ( 25 ) 3,626 3,626 — U.S. government and agency securities 803 — ( 18 ) 785 785 — Mortgage-backed securities 897 4 ( 26 ) 875 875 — Non-U.S. government and agency securities 6 — — 6 6 — Other asset-backed securities 1,066 6 ( 6 ) 1,066 1,066 — Total Level 2 6,400 33 ( 76 ) 6,357 6,357 — Level 3: Auction rate securities 36 — ( 2 ) 34 — 34 Total available-for-sale debt securities $ 6,911 $ 33 $ ( 84 ) $ 6,860 $ 6,827 $ 34 April 25, 2025 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 417 $ — $ ( 7 ) $ 410 $ 410 $ — Level 2: Corporate debt securities 3,540 17 ( 36 ) 3,521 3,521 — U.S. government and agency securities 835 — ( 20 ) 814 814 — Mortgage-backed securities 948 4 ( 29 ) 923 923 — Non-U.S. government and agency securities 6 — — 6 6 — Other asset-backed securities 1,044 5 ( 6 ) 1,044 1,044 — Total Level 2 6,373 26 ( 91 ) 6,308 6,308 — Level 3: Auction rate securities 36 — ( 3 ) 33 — 33 Total available-for-sale debt securities $ 6,826 $ 26 $ ( 100 ) $ 6,752 $ 6,719 $ 33 The amortized cost of debt securities excludes accrued interest, which is reported in othe

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) The following tables present the gross unrealized losses and fair values of the Company's available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 25, 2025 and April 25, 2025: July 25, 2025 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 606 $ ( 7 ) $ 977 $ ( 18 ) U.S. government and agency securities 127 ( 1 ) 669 ( 23 ) Mortgage-backed securities 2 ( 1 ) 540 ( 25 ) Other asset-backed securities — — 213 ( 6 ) Auction rate securities — — 34 ( 2 ) Total $ 735 $ ( 9 ) $ 2,433 $ ( 75 ) April 25, 2025 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 702 $ ( 7 ) $ 1,235 $ ( 29 ) U.S. government and agency securities 110 ( 1 ) 641 ( 25 ) Mortgage-backed securities 2 ( 1 ) 614 ( 28 ) Other asset-backed securities — — 469 ( 6 ) Auction rate securities — — 33 ( 3 ) Total $ 814 $ ( 9 ) $ 2,993 $ ( 91 ) The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three months ended July 25, 2025 and July 26, 2024. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. Gains and losses on available-for-sale debt securities are recognized in other non-operating income , net in the consolidated statements of income. During the three months ended July 25, 2025 and July 26, 2024, gross realized gains and losses on available-for-sale debt securities were not signif

View on Read The Filing